VRDN Viridian Therapeutics
- 19.960
- -0.380-1.87%
Viridian Therapeutics News
Viridian Therapeutics, Inc. (VRDN): This Small-Cap Stock Is Ready To Explode
Viridian Therapeutics (VRDN) Pioneering Breakthroughs in Thyroid Eye Disease
Viridian Therapeutics Analyst Ratings
Viridian Therapeutics: Promising FcRn Inhibitor Developments and Strong Buy Recommendation
H.C. Wainwright Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $34
In-Depth Examination Of 11 Analyst Recommendations For Viridian Therapeutics
Jefferies Releases a Buy Rating on Viridian Therapeutics (VRDN)
Jefferies Initiates Viridian Therapeutics(VRDN.US) With Buy Rating, Announces Target Price $45
A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $38 to $61
Viridian Therapeutics Price Target Maintained With a $38.00/Share by Needham
Viridian Therapeutics Reports Increased Cash Reserves Amid Losses
Positive Outlook for Viridian Therapeutics Driven by Promising VRDN-008 Data and Strategic Expansion
Viridian Therapeutics Earns Buy Rating on Promising Trial Results and Strong Financial Position
Viridian Therapeutics Advances in Biotech Innovations
Viridian Therapeutics | 10-Q: Q3 2024 Earnings Report
Viridian Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Sales Results.
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates
Viridian Therapeutics GAAP EPS of -$1.15 Misses by $0.08, Revenue of $0.09M Beats by $0.04M
Express News | Viridian Therapeutics Inc: Extends Cash Runway Into H2 2027
Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Posts Q3 Revenue $86,000
Analysis
Price Target
No Data
No Data